AZA or LDAC combined with venetoclax likely improves mortality, remission, and quality of life
New combinations show promise for older adults with myeloid leukemia
This systematic review and meta-analysis of 47 studies evaluated treatments for older adults with AML ineligible for conventional chemothera…
Combining specific drugs like venetoclax with other treatments may improve survival and quality of life for older adults with acute myeloid …
Antibody-based therapies offer potential efficacy and durability options for relapsed refractory acute myeloid leukemia patients
Review explores antibody therapies for relapsed acute myeloid leukemia
This narrative review examines antibody-based therapies for relapsed or refractory acute myeloid leukemia. The authors discuss potential eff…
A review looks at antibody-based therapies for patients with relapsed acute myeloid leukemia, comparing them to traditional treatment option…
Reduced-intensity ATRA plus arsenic with GO or low-dose anthracycline improves event-free survival in high-risk APL
New analysis shows reduced-intensity treatment works well for high-risk leukemia patients compared to standard intensive chemotherapy
This systematic review and meta-analysis of 1,323 patients with high-risk acute promyelocytic leukemia found that reduced-intensity inductio…
A large review of over 1,300 patients found that a gentler treatment plan worked just as well as harsher chemotherapy. This approach may hel…